Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1

Biochemical Pharmacology

Volumn 79, Issue 6, 2010, Pages 842-852

  Hong, Bo ^a   Lui, Vivian W Y ^a,b   Hui, Edwin P ^c   Lu, Yiling ^d   Leung, Horasis S Y ^c   Wong, Elaine Y L ^a   Cheng, Suk Hang ^a   Ng, Margaret H L ^a   Mills, Gordon B ^d   Chan, Anthony T C ^c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anti invasion; Anti proliferation; Nasopharyngeal carcinoma (NPC); Reverse phase protein array; YC 1 mechanisms

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ACETYL COENZYME A CARBOXYLASE; BETA CATENIN; CAVEOLIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG IDENTIFICATION; DRUG MECHANISM; ENZYME ACTIVATION; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDAZOLES; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN ARRAY ANALYSIS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; S PHASE;

EID: 74249106458     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.021     Document Type: Article

References (48)

1. Chan A.T., Teo P.M., and Johnson P.J. Nasopharyngeal carcinoma. Ann Oncol 13 (2002) 1007-1015
2. Spano J.P., Busson P., Atlan D., Bourhis J., Pignon J.P., Esteban C., et al. Nasopharyngeal carcinomas: an update. Eur J Cancer 39 (2003) 2121-2135
3. Anderson K.E., Mack T.M., and Silverman D.T. Cancer of the pancreas. In: Schottenfeld D., and Fraumeni Jr. J.F. (Eds). Cancer epidemiology and prevention (2006), Oxford University Press, New York 721-762
4. Skinner D.W., Van Hasselt C.A., and Tsao S.Y. Nasopharyngeal carcinoma: modes of presentation. Ann Otol Rhinol Laryngol 100 (1991) 544-551
5. Isobe K., Ito H., Shigematsu N., Kawada T., Yasuda S., Hara R., et al. Advanced nasopharyngeal carcinoma treated with chemotherapy and radiotherapy: distant metastasis and local recurrence. Int J Oncol 12 (1998) 1183-1187
6. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226-4233
7. Shin D.H., Kim J.H., Jung Y.J., Kim K.E., Jeong J.M., Chun Y.S., et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 255 (2007) 107-116
8. Pan S.L., Guh J.H., Peng C.Y., Wang S.W., Chang Y.L., Cheng F.C., et al. YC-1 [3-(5′-hydroxymethyl-2γ-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models. J Pharmacol Exp Ther 314 (2005) 35-42
9. Chun Y.S., Yeo E.J., and Park J.W. Versatile pharmacological actions of YC-1: anti-platelet to anticancer. Cancer Lett 207 (2004) 1-7
10. Chung J.G., Yang J.S., Huang L.J., Lee F.Y., Teng C.M., Tsai S.C., et al. Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 7 (2007) 3305-3317
11. Huang Y.T., Pan S.L., Guh J.H., Chang Y.L., Lee F.Y., Kuo S.C., et al. YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 4 (2005) 1628-1635
12. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95 (2003) 516-525
13. Lau C.K., Yang Z.F., Lam S.P., Lam C.T., Ngai P., Tam K.H., et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 6 (2007) 1900-1907
14. Chen C.J., Hsu M.H., Huang L.J., Yamori T., Chung J.G., Lee F.Y., et al. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol 75 (2008) 360-368
15. Wu S.Y., Pan S.L., Chen T.H., Liao C.H., Huang D.Y., Guh J.H., et al. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway. Br J Pharmacol 155 (2008) 505-513
16. Yeo E.J., Ryu J.H., Chun Y.S., Cho Y.S., Jang I.J., Cho H., et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res 66 (2006) 6345-6352
17. Tibes R., Qiu Y., Lu Y., Hennessy B., Andreeff M., Mills G.B., et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5 (2006) 2512-2521
18. Sheehan K.M., Calvert V.S., Kay E.W., Lu Y., Fishman D., Espina V., et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4 (2005) 346-355
19. Grote T., Siwak D.R., Fritsche H.A., Joy C., Mills G.B., Simeone D., et al. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8 (2008) 3051-3060
20. Charboneau L., Tory H., Chen T., Winters M., Petricoin E.F., Liotta L.A., et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 1 (2002) 305-315
21. Kim W.Y., Chang D.J., Hennessy B., Kang H.J., Yoo J., Han S.H., et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila PA) 1 (2008) 577-587
22. Zhang Q., Bhola N.E., Lui V.W., Siwak D.R., Thomas S.M., Gubish C.T., et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 6 (2007) 1414-1424
23. Lui V.W., Wong E.Y., Ho Y., Hong B., Wong S.C., Tao Q., et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 125 (2009) 1884-1893
24. Lui V.W., Boehm A.L., Koppikar P., Leeman R.J., Johnson D., Ogagan M., et al. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71 (2007) 1435-1443
25. Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, et al. A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer Lett; in press.
26. Lui V.W., Thomas S.M., Zhang Q., Wentzel A.L., Siegfried J.M., Li J.Y., et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22 (2003) 6183-6193
27. Glaser R., Zhang H.Y., Yao K.T., Zhu H.C., Wang F.X., Li G.Y., et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86 (1989) 9524-9528
28. Sizhong Z., Xiukung G., and Yi Z. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 31 (1983) 587-590
29. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73 (2004) 39-85
30. Bartek J., Lukas C., and Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5 (2004) 792-804
31. Nishizuka S., Charboneau L., Young L., Major S., Reinhold W.C., Waltham M., et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 100 (2003) 14229-14234
32. Chang M.S., Lee W.S., Teng C.M., Lee H.M., Sheu J.R., Hsiao G., et al. YC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells. Br J Pharmacol 136 (2002) 558-567
33. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 (2006) 2666-2672
34. Iiizumi M., Liu W., Pai S.K., Furuta E., and Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 1786 (2008) 87-104
35. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 (2003) 337-358
36. van Golen K.L. Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?. Expert Opin Ther Targets 10 (2006) 709-721
37. Ma B.B., Poon T.C., To K.F., Zee B., Mo F.K., Chan C.M., et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 25 (2003) 864-872
38. Li Z., Ren Y., Lin S.X., Liang Y.J., and Liang H.Z. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Chin Med J (Engl) 117 (2004) 1232-1239
39. Zhang Z.B., Cai L., Zheng S.G., Xiong Y., and Dong J.H. Overexpression of caveolin-1 in hepatocellular carcinoma with metastasis and worse prognosis: correlation with vascular endothelial growth factor, microvessel density and unpaired artery. Pathol Oncol Res (2009)
40. Kato K., Hida Y., Miyamoto M., Hashida H., Shinohara T., Itoh T., et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94 (2002) 929-933
41. Campbell L., Jasani B., Edwards K., Gumbleton M., and Griffiths D.F. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 98 (2008) 931-940
42. Thompson T.C. Metastasis-related genes in prostate cancer: the role of caveolin-1. Cancer Metastasis Rev 17 (1998) 439-442
43. Du Z.M., Hu C.F., Shao Q., Huang M.Y., Kou C.W., Zhu X.F., et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer 125 (2009) 1832-1841
44. Hsu H.K., Juan S.H., Ho P.Y., Liang Y.C., Lin C.H., Teng C.M., et al. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem Pharmacol 66 (2003) 263-271
45. Chiang W.C., Teng C.M., Lin S.L., Chen Y.M., Tsai T.J., and Hsieh B.S. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur J Pharmacol 517 (2005) 1-10
46. Wong N., Hui A.B., Fan B., Lo K.W., Pang E., Leung S.F., et al. Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet 140 (2003) 124-132
47. Ma BB, Lui VW, Poon FF, Wong SC, To KF, Wong E, et al. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs; in press.
48. Miller W.E., Earp H.S., and Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 69 (1995) 4390-4398